Asia Pacific Epigenetics Market worth $0.97 billion by 2030
The report "Asia Pacific Epigenetics Market by Offering [Enzymes, Kits & Reagents, Software, Services], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology], End User - Forecast to 2030" is projected to grow from USD 0.49 billion in 2025 and to reach USD 0.97 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 14.6% during the forecast period.
Browse 210 market data Tables and 45 Figures spread through 245 Pages and in-depth TOC on "Asia Pacific Epigenetics Market by Offering [Enzymes, Kits & Reagents, Software, Services], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology], End User - Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/asia-pacific-epigenetics-market-184019058.html
The Asia Pacific epigenetics market is growing due to expanding research funding and strong translational activity in oncology and precision medicine. Biopharma pipelines across key Asian countries are increasingly utilizing epigenetic markers for target validation, patient stratification, and monitoring therapy response. Wider adoption of multi-omics and single-cell research is also driving demand for methylation profiling, chromatin readouts, and downstream bioinformatics. Growth is further supported by a strong network of CROs and high-throughput genomics centers that run large cohort studies at scale.
The PCR & qPCR segment is expected to grow at the fastest rate during the forecast period.
By technology, the epigenetics market is segmented into NGS, PCR & qPCR, mass spectrometry, sonication, and other tools. PCR & qPCR are gaining traction as Asia-Pacific labs increasingly require cost-effective methods for methylation detection and biomarker validation, especially when moving from discovery to routine testing. PCR & qPCR platforms are well suited for targeted assays, large-cohort screening, and rapid follow-up confirmation after sequencing-based studies. Therefore, demand for this segment's offerings is expected to grow significantly during the forecast period.
The pharmaceutical and biotechnology companies segment dominated the market in 2024.
By end user, the epigenetics services market is segmented into academic and research institutes, pharma & biotech companies, and hospitals & clinics. Pharma and biotech players lead, as they invest heavily in oncology-led discovery and translational research, where methylation and chromatin signals are utilized to refine target selection and biomarker strategies. They use epigenetic tools and services for patient stratification, mechanism of action (MoA) studies, resistance mapping, and companion biomarker development to support clinical programs. Thus, these are key factors supporting the segment growth.
China is expected to be the fastest-growing region in the Asia Pacific epigenetics market during the forecast period.
By country, the Asia Pacific epigenetics market is typically viewed across China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific. China is growing the fastest, combining an expanding biopharma pipeline with a large base of universities, research institutes, and large hospitals running high-throughput genomics programs. The country is also expanding NGS capacity and downstream analytics through local ecosystems and support from CROs. Increasing oncology research output and a rising focus on drug development (biomarker-driven) are increasing demand for methylation and chromatin profiling.
Key companies in the Asia Pacific epigenetics market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), QIAGEN (Germany), along with other regional and global companies.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Asia Pacific Epigenetics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
